Jun Wang

Dr. Jun Wang


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2022 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
YLYuenan Liu
Yuenan Liu
JWJun Wang
Jun Wang
YSYi Shou
Yi Shou
WXWenjie Xu
Wenjie Xu
ZHZiwei Huang
Ziwei Huang
XZXiaoping Zhang
Xiaoping Zhang
Abnormal accumulation of lipids has been highlighted in the progression of clear cell renal cell carcinoma (ccRCC). However, the underlying mechanism remains unclear. Emerging evidence suggests long noncoding RNAs (lncRNAs) participate in the regulation of lipid metabolism. In this study, we found lncRNA COL18A1-AS1 was downregulated in ccRCC and that higher COL18A1-AS1 expression indicated better prognosis. Decreased COL18A1-AS1 expression was caused by DNA methylation at the CpG islands within its promoter. Restoring the epigenetically silenced COL18A1-AS1 repressed tumor progression, promoted lipid browning and consumption in vitro and in vivo. Mechanistically, COL18A1-AS1 could competitively bind miR-1286 to increase the expression of Krüppel-like factor 12 (KLF12). Downregulation of COL18A1-AS1 in ccRCC resulted in the low expression of KLF12. COL18A1-AS1/KLF12 positively regulated uncoupling protein 1 (UCP1)–mediated lipid browning, which promotes tumor cell “slimming” and inhibits tumor progression. When tumor cell “slimming” occurred, lipid droplets turned into tiny pieces, and lipids were consumed without producing ATP energy. Taken together, our findings on COL18A1-AS1-miR-1286/KLF12 axis revealed a potential mechanism of abnormal accumulation of lipids in ccRCC and could be a promising therapeutic target for ccRCC patients.

24 February 2025 in Cancer Research
Verified
Journal Article
Open access
SDShenghe Deng
Shenghe Deng
JWJun Wang
Jun Wang
FZFalong Zou
Falong Zou
DCDenglong Cheng
Denglong Cheng
MCMian Chen
Mian Chen
KCKailin Cai
Kailin Cai
Obstructions can occur during any stage of colorectal cancer and correspond with poor prognosis. Obstructive colorectal cancer (OCRC) is harder and exhibits increased tumor budding and proliferation of myofibroblasts compared with nonobstructive colorectal cancer, suggesting that the occurrence of obstruction may be related to extracellular matrix (ECM) remodeling. In this study, we found that colorectal cancer and OCRC samples differed substantially in ECM composition, specifically in collagen (newly formed and mature) and proteoglycans (including glycosaminoglycan, hyaluronic acid, and chondroitin sulfate). OCRC also exhibited considerable changes in ECM biomechanics and collagen arrangement. Interestingly, OCRC samples presented a notable increase in matrix cancer-associated fibroblasts (mCAF). The abundance of mCAFs correlated with the accumulation of palmitic acid (PA), and high concentrations of PA increased the secretion of ECM-related proteins by mCAFs. Additionally, PA did not directly affect normal fibroblasts but rather activated the NF-κB pathway in tumor cells to stimulate secretion of CSF1, TGFβ1, and CXCL8, which promoted the activation of normal fibroblasts into mCAFs and exacerbated ECM stiffening. Drug screening with a natural compound library identified vanillylacetone as a potential inhibitor of PA-induced cytokine secretion and ECM stiffening. These findings highlight intratumoral PA accumulation as a key mechanism driving ECM alterations and OCRC progression and suggest that targeting this axis may be useful for treating patients with colorectal cancer with risk of obstruction. Significance: Palmitic acid accumulation activates the NF-κB pathway in colorectal cancer cells to promote cytokine secretion that facilitates the generation of matrix cancer-associated fibroblasts, driving extracellular matrix remodeling and development of obstructions.

31 March 2022 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
HSHuaibing Song
Huaibing Song
JWJun Wang
Jun Wang
BXBin Xiong
Bin Xiong
JHJiayuan Hu
Jiayuan Hu
PZPei Zeng
Pei Zeng
HHHuageng Liang Huageng
Huageng Liang Huageng

31 March 2022 in Angewandte Chemie
Verified
Journal Article
Closed access
HSHuaibing Song
Huaibing Song
JWJun Wang
Jun Wang
BXBin Xiong
Bin Xiong
JHJiayuan Hu
Jiayuan Hu
PZPei Zeng
Pei Zeng
HHHuageng Liang Huageng
Huageng Liang Huageng

25 March 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
JWJun Wang
Jun Wang
HWHanwenchen Wang
Hanwenchen Wang
FZFalong Zou
Falong Zou
JGJunnan Gu
Junnan Gu
SDShenghe Deng
Shenghe Deng
KCKailin Cai
Kailin Cai
Colorectal cancer poses a significant threat to human health due to its high aggressiveness and poor prognosis. Key factors impacting patient outcomes include post-surgical recurrence, chemotherapeutic drug resistance, and insensitivity to immunotherapy. Consequently, early diagnosis and the development of effective targeted therapies are essential for improving prevention and treatment strategies. Inorganic nanomaterials have gained prominence in the diagnosis and treatment of colorectal cancer owing to their unique size, advantageous properties, and high modifiability. Various types of inorganic nanomaterials—such as metal-based, metal oxide, quantum dots, magnetic nanoparticles, carbon-based, and rare-earth nanomaterials—have demonstrated significant potential in enhancing multimodal imaging, drug delivery, and synergistic therapies. These advancements underscore their critical role in improving therapeutic outcomes. This review highlights the properties and development of inorganic nanomaterials, summarizes their recent applications and progress in colorectal cancer diagnosis and treatment, and discusses the challenges in translating these materials into clinical use. It aims to provide valuable insights for future research and the clinical application of inorganic nanomaterials in colorectal cancer management.

1 January 2026 in Bioactive Materials
Verified
Journal Article
Open access
JGJunnan Gu
Junnan Gu
YSYuxuan Sun
Yuxuan Sun
TZTianyi Zhang
Tianyi Zhang
ZJZhenxing Jiang
Zhenxing Jiang
FZFalong Zou
Falong Zou
KCKailin Cai
Kailin Cai
The accuracy of intraoperative localization of tumors undetectable under optical visualization determines surgical quality and survival outcomes in gastrointestinal cancers. Current approaches, however, remain constrained by suboptimal spatial resolution and low procedural efficiency. Additionally, conventional electromagnetic localization techniques based on image registration face challenges in soft tissue deformation scenarios. Here, we developed an electromagnetic localization technology for intraluminal tumor localization based on injectable magnetic hydrogel with sustained magnetization properties (MagLabel-IH). Following endoscopic injection into the gastrointestinal tract and in situ realignment, MagLabel-IH enables continuous intraluminal magnetic signal tracing. Intraoperatively, a dynamic registration framework synchronizes the magnetic coordinate system with real-time anatomical positions under visual guidance, achieving precise localization of optically invisible intraluminal tumors. The system demonstrated exceptional surgical instrument maneuverability (e.g., tissue grasping, resection path selection) during MagLabel-IH detection. In vivo animal evaluations demonstrated significantly enhanced localization accuracy compared to conventional biological dyes tattooing (3.8 ± 0.8 mm vs. 16.8 ± 8.6 mm, P < 0.05). Furthermore, the magnetic labels-based localization system exhibited promising utility for tumor margin demarcation and planning of gastrointestinal functional reconstruction.